After a fatty meal, intestinal enterocytes rebuild absorbed fatty acids and monoacylglycerols into triglycerides for transport in chylomicrons. Acyl-CoA acyltransferase-1 (DGAT-1) catalyzes the final acylation step, using fatty acyl-CoA and diacylglycerol. Inhibiting this enzyme helps researchers examine its contribution to dietary lipid handling, but does not leave the rest of lipid metabolism unaffected.
A Compound Designed Around a Single Enzyme
Dow and colleagues reported PF-04620110 in ACS Medicinal Chemistry Letters in 2011. Its structure combines a pyrimidooxazepinone core with a carboxylic acid group connected through a phenyl-cyclohexane spacer. The molecular formula is C21H24N4O4, and the molecular weight is approximately 396.4 g/mol.
Reading the Potency Data
The original study reported three distinct measurements:
- human DGAT-1 inhibition: IC50 of 19 nM;
- triglyceride synthesis inhibition in HT-29 cells: IC50 of 8 nM;
- DGAT-2 inhibition: IC50 greater than 30 micromolar.
The first value describes enzyme inhibition; the second measures a cellular process. Their difference does not mean the compound binds more tightly inside cells. Assay conditions and the endpoint being measured affect the result, so concentrations should be selected for the intended experimental system.
The DGAT-2 value supports selectivity within the tested range, rather than proving complete absence of activity. Since both enzymes synthesize triglycerides, this distinction helps separate their contributions. Selectivity alone, however, does not establish that every observed cellular change is caused by DGAT-1 inhibition.
Behavior in Animal Models
In rats given an oral dose of 5 mg/kg, bioavailability was reported as 100%, with a half-life of 6.8 hours. In a separate corn oil challenge, the inhibitor reduced the subsequent rise in plasma triglycerides.
This test follows the response to a single fat load over several hours. It provides functional evidence consistent with altered intestinal lipid handling, rather than directly measuring DGAT-1 activity. Plasma triglycerides also reflect lipid transport and clearance, so the response must be interpreted alongside the model, dose and sampling schedule.
Clinical Studies and Current Research Use
Human testing included single- and multiple-dose studies in otherwise healthy overweight or obese volunteers, and a multiple-dose study in people with type 2 diabetes. Entry into clinical trials does not itself establish therapeutic benefit.
For laboratory work, the compound offers a reference inhibitor for DGAT-1 biology, intestinal lipid handling and triglyceride synthesis assays. Useful study design keeps biochemical potency, cellular effects and animal responses separate, then asks how well the findings agree across these levels.
